Common Side Effects Across Ruxolitinib Brands
Ruxolitinib, sold as Jakafi (Incyte), Jakavi (Novartis), and others like generics in some markets, shares the same active ingredient and identical core safety profile. The most frequent side effects include thrombocytopenia (low platelets, 65-70% of patients), anemia (60-70%), neutropenia (20%), infections (30-40%), bruising (30%), and weight gain (20%). These occur regardless of brand due to the drug's JAK1/JAK2 inhibition, which suppresses bone marrow and immune function.[1][2]
Serious Risks and Black Box Warnings
All formulations carry FDA black box warnings for serious infections (e.g., TB, bacterial, fungal), thrombosis (blood clots), and mortality risk in polycythemia vera patients with platelets under 50,000/μL. Progressive multifocal leukoencephalopathy (PML) and secondary malignancies are also reported. Risk is dose-dependent and consistent across Jakafi, Jakavi, and approved generics.[1][3]
Differences by Brand or Formulation
No meaningful safety differences exist between branded Jakafi/Jakavi and generics (e.g., from Celgene/Sandoz or MSN Labs), as they meet bioequivalence standards. Topical ruxolitinib cream (Opzelura, Incyte) for dermatitis has a milder profile—mainly nasal swelling, diarrhea, bronchitis (10-20%)—with lower systemic absorption, avoiding hematologic risks.[4] Oral formulations show higher exposure-related risks.
How Patient Factors Affect Safety
In myelofibrosis trials, older patients (>65) or those with low baseline counts face 2-3x higher rates of severe anemia/thrombocytopenia. Long-term use (>2 years) increases non-melanoma skin cancer risk (5-10%). Monitoring requires weekly blood counts initially, then monthly.[1][2]
Comparisons with Similar JAK Inhibitors
Ruxolitinib has higher anemia rates (65%) than fedratinib (Inrebic, 40%) or pacritinib (Vonjo, 25%), but similar infection risks. It causes less GI toxicity than momelotinib (Omjjpi).[3][5]
Ongoing Safety Monitoring and Updates
Post-marketing data from 2023 labels highlight increased herpes zoster (10%) and cardiovascular events. No brand-specific recalls, but Incyte's Jakafi faced supply shortages in 2022 unrelated to safety.[1][6]
[1]: Jakafi Prescribing Information (FDA)
[2]: Jakavi Summary of Product Characteristics (EMA)
[3]: Drugs.com - Ruxolitinib Side Effects
[4]: Opzelura Prescribing Information (FDA)
[5]: NEJM - Ruxolitinib vs. Other JAK Inhibitors in Myelofibrosis
[6]: FDA Adverse Event Reporting System (FAERS) Summary